To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

RhBMP-2/ACS: Cost effective alternative to ICBG in posterolateral lumbar spinal fusion

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Author Verified
Ace Report Cover
March 2013

RhBMP-2/ACS: Cost effective alternative to ICBG in posterolateral lumbar spinal fusion

Vol: 2| Issue: 2| Number:268| ISSN#: 2564-2537
Study Type:Economic Analysis
OE Level Evidence:2
Journal Level of Evidence:N/A

The perioperative cost of Infuse bone graft in posterolateral lumbar spine fusion

Spine J. 2008 May-Jun;8(3):443-8. Epub 2007 May 15.

Contributing Authors:
Steven D Glassman Leah Y Carreon Mitchell J Campbell John R Johnson Rolando M Puno Mladen Djurasovic John R Dimar

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

102 patients, over 60 years old, scheduled to undergo an instrumented posterolateral lumbar spine fusion were randomized to receive recombinant bone morphogenetic protein rhBMP-2/ACS or Iliac crest bone graft (ICBG) during the procedure. The use of BMP is a significant cost burden to the patient and hospital. However, upon meticulous calculation of the aggregate cost in the 3 month period after su...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue